Nucana share price logo

Nucana

NASDAQ: NCNA

$1.34

+0.01

(+0.75%)

as on

Nucana Stock Performance

as on September 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.32
    $1.39
    downward going graph

    1.49%

    Downside

    3.73%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.21
    $7.22
    downward going graph

    9.70%

    Downside

    438.81%

    Upside

    downward going graph

Nucana share price movements today

Previous Close
$1.33
Open
$1.39
Volume
348.3K
Market Cap
$5.5M
Day's Low - High
$1.32 - $1.39
52 Week Low - High
$1.21 - $7.22

Nucana Historical Returns

1 Month Return
-13.55 %
3 Month Return
-29.84 %
1 Year Return
-63.69 %
3 Year Return
-99.96 %
5 Year Return
-99.99 %

Nucana Stock Fundamentals & Key Indicators

Check Nucana market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.5M

EPS (TTM)

-2.97

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.34

Industry PE ratio

-2.37

PEG Ratio

-0.0005702746284860308

EBITDA

-14.4M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-41.95%

Nucana Stock Valuation

Track how Nucana P/E has moved over time to understand its valuation trends.

Nucana in the last 5 years

  • Overview

  • Trends

Lowest (-903.08x)

March 31, 2022

Industry (-2.37x)

December 31, 2025

Today (-0.16x)

December 31, 2025

Highest (-0.16x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.16x

Nucana vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Nucana with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$5.5M-99.99%-0.340.00%0.00%
BUY$63.1B-63.24%-19.81-12.57%0.00%
BUY$130.1B174.21%29.8186.04%0.00%
BUY$79.7B21.1%18.4884.86%0.48%

Stock Returns calculator for Nucana Stock including INR - Dollar returns

The Nucana stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Nucana investment value today

Current value as on today

₹39,430

Returns

-₹60,570

(-60.57%)

Returns from Nucana Stock

-₹63,686 (-63.69%)

Dollar Impact

₹3,116 (+3.12%)

Analyst Recommendation on Nucana Stock

Based on 10 analysts

BUY

80.00%

Buy

20.00%

Hold

0.00%

Sell

Based on 10 analysts, 80% of analysts recommend a 'BUY' rating for Nucana. Average target price of $104

Nucana Share Price Target

Get share price movements and forecasts by analysts on Nucana.

What analysts predicted

98.71%UPSIDE

Target Price

$104

Current Price

$1.34

Analyzed by

10 Analysts

Target

$104.00

Nucana target price $104, a slight upside of 98.71% compared to current price of $1.34. According to 10 analysts rating.

Indian Investors' Interest in Nucana Stock

Search interest for Nucana Stock has decreased by -4% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-4% versus previous 30 day period

Nucana Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
-
-
0
Operating Income
-8
-8
-5
0
-2
-11
0
-4
-4
-3
EBITDA
-8
-8
-4
-1
-2
-11
-3
-2
-4
-3
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-8
-8
-5
0
-2
-24
0
-2
-4
-3
Income Tax Expense
-1
-1
0
0
0
0
0
0
0
0
Net Income
-6
-6
-4
0
-2
-24
0
-2
-3
-3
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Nucana Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Mar 2023
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
-
-
-
-
-
-
-
-
Gross Profit
0
-
-
-
-
-
-
-
-
Operating Income
-22
-22
-26
-36
-47
-39
-32
-22
-20
EBITDA
-
-
-
-28
-44
-42
-30
-22
-20
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-25
-18
-25
-36
-47
-38
-32
-22
-30
Income Tax Expense
-2
-4
-4
-5
-7
-6
-4
-3
-1
Net Income
-23
-13
-21
-30
-40
-32
-27
-18
-29
Net Profit Margin
100.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Nucana Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-6
-6
-4
0
-2
-24
0
-2
-3
-3
Operating Cash Flow
-5
-1
-4
-7
-3
-4
1
-1
-3
-1
Investing Cash Flow
0
0
0
0
0
0
0
0
0
0
Financing Cash Flow
1
0
4
2
0
9
15
0
0
0
Change in Cash
-4
-1
0
-4
-2
4
16
0
-2
-1

Nucana Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Mar 2023
Dec 2023
Dec 2024
Dec 2025
Net Income
-23
-13
-21
-30
-40
-32
-27
-18
-29
Operating Cash Flow
-8
-12
-23
-21
-23
-23
-26
-19
-7
Investing Cash Flow
0
0
0
-1
-3
0
2
0
0
Financing Cash Flow
77
0
0
61
0
0
0
8
25
Change in Cash
66
-9
-25
35
-27
-18
-24
-10
17

Global Institutional Holdings in Nucana

Funds
Holdings
Susquehanna International Group, LLP
0%
Citigroup Inc
0%
Citadel Advisors Llc
0.65%
Glass Jacobson Investment Advisors LLC
0.36%
Virtu Financial LLC
0.32%

Insights on Nucana

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 510.3% return, outperforming this stock by 574.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 53.7% return, outperforming this stock by 153.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, NCNA stock has moved down by -100.0%

About Nucana

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
OrganisationNucana
Headquarters3 Lochside Way, Edinburgh, MD, EH12 9DT, GB
IndustryBiotechnology
CEOHugh Stephen Griffith
E-voting on sharesClick here to vote

Key Management of Nucana

Name

Title

Prof. David Harrison

Head of Translational Medicine & Studies

Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.

Chief Medical Officer

Ms. Theresa Bruce

Chief Operating Officer

Mr. Gordon Kennovin

Senior VP of CMC & Development

Dr. Stuart Grant

Senior Vice President of Regulatory Affairs

Mr. Martin Alexander Quinn

Company Secretary

Mr. Hugh Stephen Griffith

Founder, CEO & Executive Director

Mr. Ian Webster

Chief Financial Officer

FAQs

What is Nucana share price today?

Nucana share price today is $1.34 as on at the close of the market. Nucana share today touched a day high of $1.39 and a low of $1.32.

What is the 52 week high and 52 week low for Nucana share?

Nucana share touched a 52 week high of $7.22 on and a 52 week low of $1.21 on . Nucana stock price today i.e. is closed at $1.34,which is 81.44% down from its 52 week high and 10.74% up from its 52 week low.

What is Nucana's market capitalisation today?

Nucana market capitalisation is $0.00T as on .

How to invest in Nucana Stock (NCNA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Nucana on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Nucana Shares that will get you 1.1194 shares as per Nucana share price of $1.34 per share as on September 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Nucana Stock (NCNA) from India?

Indian investors can start investing in Nucana (NCNA) shares with as little as ₹95.88 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.80 in Nucana stock (as per the Rupee-Dollar exchange rate as on ). Based on Nucana share’s latest price of $1.34 as on September 19, 2026 at 8:45 am IST, you will get 7.4627 shares of Nucana. Learn more about fractional shares .

What are the returns that Nucana has given to Indian investors in the last 5 years?

Nucana stock has given -99.99% share price returns and 30.25% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?